Noxopharm Ltd (ASX: NOX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Noxopharm Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $122.74 million
P/E Ratio 32.89
Dividend Yield N/A
Shares Outstanding 292.24 million
Earnings per share -0.035
Dividend per share N/A
Year To Date Return 2.56%
Earnings Yield 3.04%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Noxopharm Ltd (ASX: NOX)
Latest News

NOX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Noxopharm Ltd

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

NOX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
20 Jan 2022 $0.42 $0.02 5.00% 254,108 $0.40 $0.43 $0.40
19 Jan 2022 $0.40 $-0.04 -9.20% 516,032 $0.44 $0.44 $0.40
18 Jan 2022 $0.44 $0.01 2.33% 33,884 $0.44 $0.45 $0.44
17 Jan 2022 $0.43 $-0.04 -8.60% 672,278 $0.47 $0.47 $0.43
14 Jan 2022 $0.47 $0.02 4.49% 359,443 $0.46 $0.48 $0.45
13 Jan 2022 $0.45 $-0.02 -4.35% 212,301 $0.46 $0.46 $0.45
12 Jan 2022 $0.46 $0.02 4.55% 252,066 $0.44 $0.46 $0.44
11 Jan 2022 $0.44 $0.02 4.76% 187,491 $0.42 $0.44 $0.42
10 Jan 2022 $0.42 $-0.01 -2.35% 200,586 $0.43 $0.43 $0.42
07 Jan 2022 $0.43 $0.03 7.50% 358,082 $0.42 $0.43 $0.42
06 Jan 2022 $0.40 $-0.04 -9.20% 251,435 $0.44 $0.44 $0.40
05 Jan 2022 $0.44 $0.03 7.32% 334,765 $0.42 $0.44 $0.42
04 Jan 2022 $0.41 $0.02 5.13% 309,016 $0.40 $0.43 $0.40
31 Dec 2021 $0.39 $0.01 2.63% 38,490 $0.39 $0.40 $0.38
30 Dec 2021 $0.38 $-0.02 -5.06% 146,795 $0.40 $0.40 $0.38
29 Dec 2021 $0.40 $0.02 5.26% 313,373 $0.38 $0.40 $0.38
24 Dec 2021 $0.38 $0.00 0.00% 115,089 $0.37 $0.38 $0.36
23 Dec 2021 $0.38 $0.01 2.70% 172,282 $0.38 $0.39 $0.37
22 Dec 2021 $0.37 $0.03 8.82% 649,991 $0.32 $0.37 $0.32

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
01 Dec 2021 Graham Kelly Expiry 37 $16,296
Options expired.
31 May 2021 Frederick (Fred) Bart Issued 3 $1,580,137
Issue of securities.
31 May 2021 Boris Patkin Issued 250 $183,750
Director remuneration.
29 Apr 2021 Boris Patkin Cancelled 250 $150,000
Cancellation of securities.
26 Feb 2021 Graham Kelly Exercise 8 $2,400,000
Exercise of options.
26 Feb 2021 Graham Kelly Buy 8 $2,400,000
Exercise of options.
26 Feb 2021 Graham Kelly Expiry 4 $2,791,375
Options expired.
26 Feb 2021 Peter Marks Exercise 200 $60,000
Exercise of options.
26 Feb 2021 Peter Marks Buy 200 $60,000
Exercise of options.
23 Feb 2021 Graham Kelly Sell 8 $5,760,000
Off-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Frederick (Fred) Bart Non-Executive DirectorNon-Executive Chairman May 2020
Mr Bart was appointed the Managing Director of Textile Industries Australia. The Group employed over 1,200 people and distributed product to many countries worldwide. The Company manufactured and distributed the majority of bed linen in Australia under brands like Sheridan and ACTIL. The Company was sold in 1987. In 1989, Mr Bart established and chairs a number of private companies under the umbrella of the Bart Group which covered hotels, retail, commercial and residential land development and technologies which still continue to operate. The Group today employs in excess of 1,000 people and is active in many local and overseas markets. In 2001, Mr Bart became Chairman of Electro Optic Systems Holdings Limited (ASX: EOS). Since that time it has grown to be one of Australia's premier defence companies with activities in many countries worldwide employing over 400 people and is currently included in the S&P/ASX 300. In September 2000, Mr Bart became a director and Chairman of Audio Pixels Holdings Limited (ASX: AKP). Audio Pixels is developing the first digital speaker in the world and currently has a market capitalisation of over $600m. In 2013, Mr Bart became Chairman and majority shareholder of Immunovative Therapies Limited, a private Israeli company involved in the manufacture of vaccines for the treatment of certain forms of cancer. The Company has undertaken trials in both collateral and liver cancers. In March 2018, Mr Bart joined the Board of Weebit Nano Limited (ASX: WBT). Weebit is a developer of memory technology (1,000 X faster, 1,000 X more energy efficient and 100X higher endurance) than existing flash memory technologie Fred Bart is Chairman of ASX listed companies, Electro Optic Systems Holdings Limited and Audio Pixels Holdings Limited and is a director of Weebit Nano Limited. Mr Bart is also a director of Immunovative Therapies Limited, an Israeli company involved in in the manufacture of cancer vaccines for the treatment of most forms of cancer.
Mr Peter Ashley Marks Non-Executive DirectorNon-Executive Deputy Chairman Mar 2016
Mr Marks has over 35 years' experience in corporate advisory, and investment banking. Over the course of his long career, he has specialised in capital raising IPOs, cross border, M&A transactions, corporate underwriting and venture capital transactions for companies in Australia, the US and Israel. He has been involved in a broad range of transactions with a special focus in the life sciences, biotechnology, medical technology and high tech segments. Mr Marks has served as both an Executive and Non-Executive Director of a number of different entities which have been listed on the ASX, Nasdaq and AIM markets
Mr Boris Patkin Non-Executive Director Mar 2020
Mr Patin brings market knowledge, thorough research and years of experience in investment markets and Business Consulting. Mr Patin's experience lends itself to Financial and Investment advising but also as a business consultant to further enhance business opportunities in Medical technology and in sourcing other opportunities to enhance investments. Mr Patin has worked with Israeli companies to explore various opportunities in the Medical and disruptive technology space. Mr Patin has developed an in-depth understanding of industry trends and gained valuable insight into domestic and international markets. Mr Patin has specialised in reconstruction of Companies, Investments and International trade. He has experience in developing and adding value to public listed companies, especially in the Medical, Resources and Retirement space.
Dr Graham E Kelly Executive DirectorChief Executive OfficerManaging Director Apr 2019
Mr Mr Kelly, after graduation joined the newly formed Department of Transplant Surgery in the Faculty of Medicine at The University of Sydney, gaining a Doctor of Philosophy in 1972. The subject of his PhD thesis was the manufacture and use of a novel drug for the treatment of tissue rejection in kidney transplant recipients, with that drug subsequently being commercialised and used globally in kidney transplantation. Mr Kelly was appointed Senior Research Fellow in Experimental Surgery at The University of Sydney, contributing through research in the areas of organ recovery for transplantation and liver transplant surgery. The increased susceptibility of organ transplant recipients to malignant cancer eventually led Mr Kelly to focus on the causes of that phenomenon, and in turn, to the broader issue of the link between diet and the incidences of certain cancers. The latter area of research led to a research interest in dietary isoflavones and their role in human health. Mr Kelly developed a theory that dietary isoflavones were metabolised within the body into novel chemicals that possessed important hormone like functions, and as such made important contributions to human health. That theory provided the basis for Mr Kelly leaving academia and founding the company, Norvet Ltd, which listed on the ASX in 1994. That company subsequently changed its name to Novogen Ltd and listed in the US on NASDAQ (1998). Mr Kelly was variously CEO, Executive Chairman and an Executive Director of Novogen, 1994 - 2006. He also was Executive Chairman of Marshall Edwards Inc (MEI) which listed on London's AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma Inc. Mr Kelly resigned from his executive and Board positions at Novogen and MEI in 2006. In early 2012, Mr Kelly addressed the matter of the transport of isoflavones in the blood of humans, conducting formulation studies in a private capacity that led shortly thereafter to the concept behind NOX66. After leaving Novogen in 2015, Mr Kelly established private biotechnology company Noxopharm Limited in order to commercialise NOX66. Noxopharm became a public company in August 2016. Mr Kelly was also the founder of a fourth biotechnology company, Nyrada Inc. in September 2017. Nyrada (ASX:NYR) became a public company in January 2020. Nyrada is a drug development company with a focus on cardiovascular and traumatic brain injury treatments. Noxopharm is currently the major shareholder. He was a former director of Nyrada Inc.
Mr David James Franks Company Secretary Jan 2017
-
David James Franks Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
MILLIGENE PTY LTD (THE GE + PR KELLY FAM TRUST) 27,649,106 9.59%
MRS ELEANORE GOODRIDGE 9,727,989 3.38%
MILLIGENE PTY LTD (THE GE + PR KELLY FAM TRUST) I 8,000,000 2.78%
KALE CAPITAL CORPORATION LTD 7,205,290 2.50%
Citicorp Nominees Pty Limited 7,120,438 2.47%
RGT CAPITAL FUND NO 5 (NOXO) PTY LTD 6,500,333 2.26%
LINK TRADERS (AUST) PTY LTD 5,430,965 1.88%
LINK TRADERS (AUST) PTY LTD I 5,041,224 1.75%
GRANDOR PTY LTD MARK SCOTT FAMILY P/F A/C 3,995,850 1.39%
RHLC PTY LIMITED RHLC S/F A/C 3,550,000 1.23%
NORA GOODRIDGE INVESTMENTS PTY LIMITED 3,090,489 1.07%
BART SUPERANNUATION PTY LIMITED 4F INVESTMENTS SUPERFUND A/C 3,080,189 1.07%
SUBURBAN HOLDINGS PTY LTD THE SUBURBAN SUPER FUND A/C 3,051,677 1.06%
JAMBER INVESTMENTS PTY LTD THE AMBER SCHWARZ SUPER FUND A/C 2,752,762 0.96%
BLACKCOURT (NSW) PTY LIMITED LAWSAM SUPER FUND A/C 2,596,276 0.90%
MR FREDERICK BART 2,538,462 0.88%
HSBC Custody Nominees (Australia) Limited 2,514,109 0.87%
OGEN NOMINEES PTY LTD 2,300,000 0.80%
HALCYON NOMINEES PTY LTD HALCYON SUPER FUND A/C 2,000,000 0.69%
HELIUM MANAGEMENT PTY LTD HELIUM S/F A/C 1,931,246 0.67%

Profile

since

Note